If you are an Aetna member and received a letter regarding contract negotiations with NewYork-Presbyterian, you may find out the latest information here.

John N. Allan, M.D.

Hematology/Oncology

Locations and Appointments

Insurances Accepted

Please contact the doctor's office to verify that your insurance is accepted.

  • HMO
  • Medicare
  • PPO
  • EPO/POS
  • CHP
  • Blue Access
  • Blue Connection
  • EPO
  • HMO
  • Mediblue (Senior)
  • PPO
  • CBP
  • Medicaid
  • Medicare
  • Freedom
  • Liberty
  • Medicare Advantage
  • Metro/Core/Charter
  • Community Plan
  • Medicare
  • HMO
  • Medicare
Personal Statement

Our Lymphoma group has been at the forefront in the development of targeted therapies for CLL and other lymphoid malignancies. We strive to bring effective therapeutics to patients, years before they are widely available. I am fortunate to practice oncology in such an exciting era with rapidly improving diagnostic and therapeutic options. I seek to incorporate the latest breakthroughs and technology in providing care to my patients. Comprehensive in my approach, I am driven to understand the underlying biology of the disease, individualizing each patient’s treatment plan. I offer patients a unique experience, with compassion for the patient and their family. With a large portfolio of clinical trials, our group offers ample opportunities for patients to participate in clinical research. Our hospital system is award winning and provides access to world-class consultants for all medical conditions. It will be a privilege to care for you or your family member. 

Biographical Info

Dr. Allan is an Associate Professor of Clinical Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. Dr. Allan completed his undergraduate education at the University of Missouri-Columbia and graduated with a B.S. in both Biochemistry and Finance. He subsequently obtained his medical degree from Saint Louis University. Seeking an internal medicine residency program with particular strength in oncology, Dr. Allan moved to New York in 2009 to train at NewYork-Presbyterian Hospital, Weill Cornell Medical Campus, where he also completed his hematology and medical oncology fellowship.

Upon completion of training Dr. Allan joined the lymphoma faculty in the Division of Hematology and Oncology and is a member of the CLL Research Center.  Dr. Allan treats all lymphoid malignancies and has a particular interest in improving therapies for patients with CLL and Richter’s Syndrome, which is the focus of his research. 

Honors and Awards

2002 Alpha Sigma Nu Jesuit Honor Society

2008 Alpha Omega Alpha

2009 Arnold P. Gold Humanism in Medicine Honor Society

2014 Recipient Susan Murphy Fellowship Award

Board Certifications
American Board of Internal Medicine
American Board of Internal Medicine (Hematology)
American Board of Internal Medicine (Medical Oncology)
Clinical Expertise
CLL (Chronic Lymphocytic Leukemia)
Lymphoma
Immunotherapy
Languages
English
Education 
  • M.D.
    St. Louis University School of Medicine
    2009
  • B.S.
    University of Missouri
    2003
Appointments 
  • David M. Nanus, MD Clinical Scholar in Cancer
    Weill Cornell Medical College, Cornell University
  • Associate Attending Physician
    NewYork-Presbyterian Hospital
  • Associate Professor of Clinical Medicine
    Weill Cornell Medical College, Cornell University

Relationships and collaborations with for-profit and not-for profit organizations are of vital importance to our faculty because these exchanges of scientific information foster innovation. As experts in their fields, WCM physicians and scientists are sought after by many organizations to consult and educate. WCM and its faculty make this information available to the public, thus creating a transparent environment.

Consultant: 
AbbVie Inc.
ADC Therapeutics
AstraZeneca Pharmaceuticals LP
BeiGene USA
Eli Lilly and Company
Epizyme
Genentech, Inc.
Janssen Pharmaceutical Company
KLJ Associates, Inc.
Professional Services: 
Projects In Knowledge, Inc.
Speaker/Lecturer: 
AbbVie Inc.
Aptitude Health
BeiGene USA
Clinical Care Options, LLC
Dava Oncology
Janssen Pharmaceutical Company
MLI-Peerview
Pharmacyclics, Inc.
Prime Oncology
Rockpointe Corporation